---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-202865"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2025-09-15T23:59:59+00:00"
generated_at: "2026-05-17T06:36:30.300077+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma Phase 3 EFZO-FIT study misses primary endpoint in pulmonary sarcoidosis

## Summary
- Primary endpoint: change from baseline in mean daily OCS dose at week 48; p=0.3313 (2.79 mg efzofitimod vs 3.52 mg placebo).
- Nominal KSQ-Lung score improvement for 5.0 mg/kg vs placebo (p=0.0479); steroid withdrawal with KSQ-Lung improvement p=0.0199.
- FVC maintained; safety consistent with prior trials; company plans to engage FDA on path forward.
- Study enrolled 268 patients; hierarchical testing stopped after primary miss; all subsequent p-values nominal.

## SEC filing metadata
- accession: 0001193125-25-202865
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2025-09-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000119312525202865/0001193125-25-202865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000119312525202865/atyr-20250915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-202865
- JSON: https://secwatch.observer/filing/0001193125-25-202865.json
- Plain text: https://secwatch.observer/filing/0001193125-25-202865.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.